Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.68 |
| ▸ | MEN1 | O00255 | 5/20 | 0.68 |
| ▸ | RAB9A | P51151 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 7/20 | 0.57 |
| ▸ | TP53 | P04637 | 4/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2930341 | 0.91 | KMT2A (0.73) | KMT2AMEN1RAB9AMAPTTP53 | |
| SCHEMBL2928399 | 0.85 | KMT2A (0.69) | KMT2AMEN1RAB9AMAPTTP53 | |
| SCHEMBL2930743 | 0.84 | KMT2A (0.67) | KMT2AMEN1RAB9AMAPTTP53 | |
| SCHEMBL2925398 | 0.83 | RAB9A (0.79) | KMT2AMEN1RAB9AMAPTTP53 | |
| SCHEMBL2929230 | 0.81 | KMT2A (0.66) | KMT2AMEN1RAB9AMAPTTP53 | |
| SCHEMBL2928990 | 0.81 | KMT2A (1.00) | KMT2AMEN1RAB9AMAPTTP53 | |
| SCHEMBL2928891 | 0.81 | KMT2A (0.84) | KMT2AMEN1RAB9AMAPTTP53 | |
| SCHEMBL2927849 | 0.81 | MAPT (0.69) | KMT2AMEN1RAB9AMAPTTP53 | |
| SCHEMBL2930509 | 0.78 | KMT2A (0.79) | KMT2AMEN1RAB9AMAPTTP53 | |
| SCHEMBL2930576 | 0.78 | RAB9A (0.86) | KMT2AMEN1RAB9AMAPTTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8431602-B2 | Beta-amino acid derivatives for treatment of diabetes | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2013-04-30 | — | — | US | claimed |
| EP-2231640-B1 | BETA-AMINO ACID DERIVATIVES FOR TREATMENT OF DIABETES | MERCK PATENT GMBH (DE) | 2012-06-06 | — | — | EP | claimed |
| US-20100331346-A1 | BETA-AMINO ACID DERIVATIVES FOR TREATMENT OF DIABETES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2010-12-30 | — | — | US | claimed |
| US-8431602-B2 | Beta-amino acid derivatives for treatment of diabetes | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2013-04-30 | — | — | US | disclosed |
| US-8431602-B2 | Beta-amino acid derivatives for treatment of diabetes | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2013-04-30 | — | — | US | disclosed |
| US-20120142705-A1 | ISATIN AND OXINDOLE COMPOUNDS | KESTER ROBERT FRANCIS (US) | 2012-06-07 | — | — | US | disclosed |
| EP-2231640-B1 | BETA-AMINO ACID DERIVATIVES FOR TREATMENT OF DIABETES | MERCK PATENT GMBH (DE) | 2012-06-06 | — | — | EP | disclosed |
| EP-2231640-B1 | BETA-AMINO ACID DERIVATIVES FOR TREATMENT OF DIABETES | MERCK PATENT GMBH (DE) | 2012-06-06 | — | — | EP | disclosed |
| US-20100331346-A1 | BETA-AMINO ACID DERIVATIVES FOR TREATMENT OF DIABETES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2010-12-30 | — | — | US | disclosed |
| US-20100331346-A1 | BETA-AMINO ACID DERIVATIVES FOR TREATMENT OF DIABETES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2010-12-30 | — | — | US | disclosed |
| EP-2231640-A1 | BETA-AMINO ACID DERIVATIVES FOR TREATMENT OF DIABETES | Merck Patent GmbH (DE) | 2010-09-29 | — | — | EP | disclosed |
| WO-2009092432-A1 | BETA-AMINO ACID DERIVATIVES FOR TREATMENT OF DIABETES | MERCK PATENT GMBH (DE) | 2009-07-30 | — | — | WO | disclosed |
| WO-2009092432-A1 | BETA-AMINO ACID DERIVATIVES FOR TREATMENT OF DIABETES | MERCK PATENT GMBH (DE) | 2009-07-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331346-A1 | BETA-AMINO ACID DERIVATIVES FOR TREATMENT OF DIABETES | GPR119, GLS, GCKR | KMT2A 3191/4885MEN1 3909/4885RAB9A 2655/4885 |
| US-20120142705-A1 | ISATIN AND OXINDOLE COMPOUNDS | GPR119, INSR, OAT | KMT2A 4201/4885MEN1 2086/4885RAB9A 1778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.